» Articles » PMID: 38866560

The Art of Finding the Right Drug Target: Emerging Methods and Strategies

Overview
Journal Pharmacol Rev
Specialty Pharmacology
Date 2024 Jun 12
PMID 38866560
Authors
Affiliations
Soon will be listed here.
Abstract

Drug targets are specific molecules in biological tissues and body fluids that interact with drugs. Drug target discovery is a key component of drug discovery and is essential for the development of new drugs in areas such as cancer therapy and precision medicine. Traditional in vitro or in vivo target discovery methods are time-consuming and labor-intensive, limiting the pace of drug discovery. With the development of modern discovery methods, the discovery and application of various emerging technologies have greatly improved the efficiency of drug discovery, shortened the cycle time, and reduced the cost. This review provides a comprehensive overview of various emerging drug target discovery strategies, including computer-assisted approaches, drug affinity response target stability, multiomics analysis, gene editing, and nonsense-mediated mRNA degradation, and discusses the effectiveness and limitations of the various approaches, as well as their application in real cases. Through the review of the aforementioned contents, a general overview of the development of novel drug targets and disease treatment strategies will be provided, and a theoretical basis will be provided for those who are engaged in pharmaceutical science research. SIGNIFICANCE STATEMENT: Target-based drug discovery has been the main approach to drug discovery in the pharmaceutical industry for the past three decades. Traditional drug target discovery methods based on in vivo or in vitro validation are time-consuming and costly, greatly limiting the development of new drugs. Therefore, the development and selection of new methods in the drug target discovery process is crucial.

Citing Articles

Selenium: 48-year journey of global clinical trials.

Wu Y, Pei J, Xu Y, Yu F, Xu S Mol Cell Biochem. 2025; .

PMID: 39755855 DOI: 10.1007/s11010-024-05202-x.


A comprehensive review of integrated management strategies for damping-off disease in chili.

Delai C, Muhae-Ud-Din G, Abid R, Tian T, Liu R, Xiong Y Front Microbiol. 2024; 15:1479957.

PMID: 39483761 PMC: 11524829. DOI: 10.3389/fmicb.2024.1479957.


Evolution and stress response potential of the plant splicing factor U1C.

Jia Z, Wang J, Meng X, Yang X, Tian Y, Wang B Sci Rep. 2024; 14(1):17212.

PMID: 39060315 PMC: 11282270. DOI: 10.1038/s41598-024-68190-4.

References
1.
Auwul M, Rahman M, Gov E, Shahjaman M, Moni M . Bioinformatics and machine learning approach identifies potential drug targets and pathways in COVID-19. Brief Bioinform. 2021; 22(5). PMC: 8083354. DOI: 10.1093/bib/bbab120. View

2.
Aviles-Alia A, Zulaica J, Perez J, Rubio-Martinez J, Geller R, Granadino-Roldan J . The Discovery of inhibitors of the SARS-CoV-2 S protein through computational drug repurposing. Comput Biol Med. 2024; 171:108163. DOI: 10.1016/j.compbiomed.2024.108163. View

3.
Karousis E, Muhlemann O . Nonsense-Mediated mRNA Decay Begins Where Translation Ends. Cold Spring Harb Perspect Biol. 2018; 11(2). PMC: 6360860. DOI: 10.1101/cshperspect.a032862. View

4.
Jost M, Chen Y, Gilbert L, Horlbeck M, Krenning L, Menchon G . Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent. Mol Cell. 2017; 68(1):210-223.e6. PMC: 5640507. DOI: 10.1016/j.molcel.2017.09.012. View

5.
Wang R, Wang M, Zhou J, Dai Z, Sun G, Sun X . Calenduloside E suppresses calcium overload by promoting the interaction between L-type calcium channels and Bcl2-associated athanogene 3 to alleviate myocardial ischemia/reperfusion injury. J Adv Res. 2022; 34:173-186. PMC: 8655133. DOI: 10.1016/j.jare.2020.10.005. View